Jiangsu Hengrui Medicine Co Ltd (600276) - Total Liabilities
Based on the latest financial reports, Jiangsu Hengrui Medicine Co Ltd (600276) has total liabilities worth CN¥8.30 Billion CNY (≈ $1.21 Billion USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Jiangsu Hengrui Medicine Co Ltd (600276) net asset momentum to track the company's year-over-year net asset growth rate.
Jiangsu Hengrui Medicine Co Ltd - Total Liabilities Trend (1997–2024)
This chart illustrates how Jiangsu Hengrui Medicine Co Ltd's total liabilities have evolved over time, based on quarterly financial data. See 600276 FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
Jiangsu Hengrui Medicine Co Ltd Competitors by Total Liabilities
The table below lists competitors of Jiangsu Hengrui Medicine Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
CITIC Securities Co Ltd
SHG:600030
|
China | CN¥1.90 Trillion |
|
Cencora Inc.
NYSE:COR
|
USA | $78.07 Billion |
|
Rockwell Automation Inc
NYSE:ROK
|
USA | $7.68 Billion |
|
Hangzhou Hikvision Digital Technology Co Ltd
SHE:002415
|
China | CN¥40.94 Billion |
|
HOYA CORP. ADR/ 1 O.N.
F:HYB0
|
Germany | €262.65 Billion |
|
Discover Financial Services
NYSE:DFS
|
USA | $128.95 Billion |
|
Itaú Unibanco Holding S.A.
SA:ITUB3
|
Brazil | R$2.95 Trillion |
|
Vistra Energy Corp
NYSE:VST
|
USA | $32.80 Billion |
Liability Composition Analysis (1997–2024)
This chart breaks down Jiangsu Hengrui Medicine Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Jiangsu Hengrui Medicine Co Ltd market cap and net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.55 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.14 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.12 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Jiangsu Hengrui Medicine Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Jiangsu Hengrui Medicine Co Ltd (1997–2024)
The table below shows the annual total liabilities of Jiangsu Hengrui Medicine Co Ltd from 1997 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥4.05 Billion ≈ $591.97 Million |
+47.03% |
| 2023-12-31 | CN¥2.75 Billion ≈ $402.62 Million |
-30.20% |
| 2022-12-31 | CN¥3.94 Billion ≈ $576.82 Million |
+6.70% |
| 2021-12-31 | CN¥3.69 Billion ≈ $540.61 Million |
-6.29% |
| 2020-12-31 | CN¥3.94 Billion ≈ $576.92 Million |
+50.54% |
| 2019-12-31 | CN¥2.62 Billion ≈ $383.23 Million |
+2.16% |
| 2018-12-31 | CN¥2.56 Billion ≈ $375.12 Million |
+22.29% |
| 2017-12-31 | CN¥2.10 Billion ≈ $306.74 Million |
+44.00% |
| 2016-12-31 | CN¥1.46 Billion ≈ $213.01 Million |
+27.81% |
| 2015-12-31 | CN¥1.14 Billion ≈ $166.66 Million |
+42.91% |
| 2014-12-31 | CN¥796.98 Million ≈ $116.62 Million |
+41.21% |
| 2013-12-31 | CN¥564.40 Million ≈ $82.59 Million |
+25.42% |
| 2012-12-31 | CN¥450.01 Million ≈ $65.85 Million |
+2.40% |
| 2011-12-31 | CN¥439.47 Million ≈ $64.31 Million |
+4.44% |
| 2010-12-31 | CN¥420.80 Million ≈ $61.58 Million |
+26.04% |
| 2009-12-31 | CN¥333.85 Million ≈ $48.85 Million |
+45.21% |
| 2008-12-31 | CN¥229.91 Million ≈ $33.64 Million |
-39.58% |
| 2007-12-31 | CN¥380.51 Million ≈ $55.68 Million |
+89.24% |
| 2006-12-31 | CN¥201.07 Million ≈ $29.42 Million |
+13.53% |
| 2005-12-31 | CN¥177.10 Million ≈ $25.92 Million |
-31.18% |
| 2004-12-31 | CN¥257.33 Million ≈ $37.66 Million |
-52.99% |
| 2003-12-31 | CN¥547.34 Million ≈ $80.09 Million |
+38.71% |
| 2002-12-31 | CN¥394.60 Million ≈ $57.74 Million |
+9.30% |
| 2001-12-31 | CN¥361.03 Million ≈ $52.83 Million |
+15.09% |
| 2000-12-31 | CN¥313.71 Million ≈ $45.91 Million |
+4.16% |
| 1999-12-31 | CN¥301.17 Million ≈ $44.07 Million |
+34.45% |
| 1998-12-31 | CN¥224.00 Million ≈ $32.78 Million |
+15.83% |
| 1997-12-31 | CN¥193.38 Million ≈ $28.30 Million |
-- |
About Jiangsu Hengrui Medicine Co Ltd
Jiangsu Hengrui Pharmaceuticals Co.,Ltd, a pharmaceutical company, researches, develops, manufactures, and commercializes medicines to address unmet clinical needs in China and internationally. It develops medicines in the areas of oncology, metabolic and cardiovascular, immunological and respiratory, neuroscience, pain management, infectious, respiratory system, hematological, ophthalmology, and… Read more